2023
The impact of anti-malarial markets on artemisinin resistance: perspectives from Burkina Faso
Guissou R, Amaratunga C, de Haan F, Tou F, Cheah P, Yerbanga R, Moors E, Dhorda M, Tindana P, Boon W, Dondorp A, Ouédraogo J. The impact of anti-malarial markets on artemisinin resistance: perspectives from Burkina Faso. Malaria Journal 2023, 22: 269. PMID: 37705004, PMCID: PMC10498571, DOI: 10.1186/s12936-023-04705-0.Peer-Reviewed Original ResearchConceptsDepth interviewsGroup discussionsNational policy makersDrug marketBurkina FasoFocus group discussionsPolicy publicationsPublic policyCommunity membersFunding systemPolicy makersAfrican countriesPolicyAnti-malarial policyMarket characteristicsAnti-malarial marketInterviewsRepresentative sampleGrey literatureMarketFasoPerspectiveEmergenceTerms of availabilityDiscussion
2021
To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies?
de Haan F, Bolarinwa O, Guissou R, Tou F, Tindana P, Boon W, Moors E, Cheah P, Dhorda M, Dondorp A, Ouedraogo J, Mokuolu O, Amaratunga C. To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies? PLOS ONE 2021, 16: e0256567. PMID: 34464398, PMCID: PMC8407563, DOI: 10.1371/journal.pone.0256567.Peer-Reviewed Original ResearchConceptsAfrican countriesTriple artemisinin-based combination therapiesKey actor groupsMarket prospectsBurkina FasoActor groupsInnovation systemRegulatory arrangementsDepth interviewsInternational fundersArtemisinin-based combination therapyProfit motivesQualitative studySoutheast AsiaGroup discussionsCountry levelAfrican countiesCurrent artemisinin-based combination therapiesLarger communityCountriesDrug marketAcceptability issuesBroad implicationsWorld Health OrganizationMarket readiness